Edison Investment Research - INTEC PHARMA (NTEC) Intec Pharma - Ongoing AP clinical trials

Report

Edison Investment Research

Maxim Jacobs

Intec Pharma - Ongoing AP clinical trials

Intec Pharmaâ€™s clinical programmes to validate the utility of its unique drug delivery platform, the accordion pill (AP), are ongoing. The company announced with its Q317 report that patient enrolment for the Phase III AP-CDLD (carbidopa and levodopa) in Parkinsonâ€™s has been increased to 420 patients (from 328). We now expect full enrolment in Q318. Additionally, Intec is redesigning AP-CBD/THC (cannabidiol and tetrahydrocannabinol) for a second Phase I trial and the indication is not yet specified.

08/01/2018 11 EN

Underlying

INTEC PHARMA

See profile

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Maxim Jacobs

Other Reports on these Companies

Edison Investment Research

Intec Pharma - Continued confidence in AP-CDLD

Intec Pharma has developed a unique drug delivery platform, the accordion pill (AP) and is enrolling a 420-patient trial of AP-CDLD for Parkinsonâ€™s disease (PD), with full enrolment expected in Q318. Many of the adverse effects associated with the treatment of PD with levodopa (the standard of care), such as off-time and troublesome dyskinesia, are directly associated with its pharmacokinetic (PK) profile. Recently released data from two PK studies of AP-CDLD showed their formulation had lower peak serum concentrations and a longer half-life, which should lower these side effects.

July 23, 2018 July 23, 2018 6 EN

Edison Investment Research

Intec Pharma - Bolstering the case for AP-CDLD

Intec Pharma recently released the results from two pharmacokinetic (PK) studies of AP-CDLD (n=18 and n=30). The data showed trends towards lower peak serum concentrations (Cmax) and a longer half-life (T1/2, although there was some inconsistency), which should reduce dyskinesia and off-time, respectively. Additionally, one study measured food effect, which was present but did not delay onset of effects, unlike the approved extended-release carbidopa/levodopa formulation, Rytary.

May 21, 2018 May 21, 2018 6 EN

Edison Investment Research

Intec Pharma - Phase III more than half the way there

The year 2017 was marked by steady progress in Intecâ€™s development program of AP-CDLD for the treatment of Parkinsonâ€™s disease (PD). The drug is a co-formulation of widely used carbidopa and levodopa using the companyâ€™s proprietary accordion pill (AP) technology. The program is in Phase III with more than 300 (of 420) patients enrolled to date with full enrolment expected in H218.

March 22, 2018 March 22, 2018 6 EN

Manx Financial Group - Termination of coverage

Edison Investment Research is terminating coverage on Manx Financial Group (MFX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 10, 2025 March 10, 2025 1 EN

Kate Heseltine

Kate Heseltine

musicMagpie - Termination of coverage

Edison Investment Research is terminating coverage on musicMagpie (MMAG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 5, 2025 March 5, 2025 1 EN

Kate Heseltine

Kate Heseltine

Topps Tiles - Accelerating growth through Q125

Topps Tiles (TPT) is enjoying a return to revenue growth following a very challenging FY24 due to wider macroeconomic weakness. The company’s recovery is clearly being boosted by new revenue streams from its self-help initiatives, notably from trade and online customers across all of its brands. While the macroeconomic environment remains uncertain, it is pleasing that the strategy is supporting growth. The valuation continues to look compelling, even with limited macroeconomic recovery included in management’s long-term financial goals. With the Q125 trading update, the CEO has announced his ...

January 10, 2025 January 10, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Intec Pharma - Ongoing AP clinical trials

Intec Pharma - Continued confidence in AP-CDLD

Intec Pharma - Bolstering the case for AP-CDLD

Intec Pharma - Phase III more than half the way there

Manx Financial Group - Termination of coverage

musicMagpie - Termination of coverage

Topps Tiles - Accelerating growth through Q125

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe